PMID- 17996672
OWN - NLM
STAT- MEDLINE
DCOM- 20080124
LR  - 20131121
IS  - 1567-5769 (Print)
IS  - 1567-5769 (Linking)
VI  - 7
IP  - 13
DP  - 2007 Dec 15
TI  - Effects of developmental hypothyroidism induced by maternal administration of 
      methimazole or propylthiouracil on the immune system of rats.
PG  - 1630-8
AB  - Methimazole (MMI) and propylthiouracil (PTU) are popularly used antithyroid drugs 
      (ATDs) for the treatment of Graves' hyperthyroidism. The aim of the present study 
      was to determine the effects of ATDs on the developing immune system of the rats. 
      Maternal Sprague-Dawley rats were given drinking water containing 200 ppm of MMI, 
      12 ppm of PTU (high-dose PTU), or 3 ppm of PTU (low-dose PTU) between gestational 
      day (GD) 10 and postnatal week (PNW) 3. Exposure to the ATDs was ceased upon 
      weaning at PNW3, and the male offspring were sampled at PNWs 3 or 11. The serum 
      thyroid-related hormone levels and the hematological components in the offspring 
      were then determined. The expressions of surface markers in the spleen, thymus 
      and peripheral blood were determined using flowcytometry. The weights of the 
      body, spleen and thymus and the splenic and thymic cell numbers were decreased in 
      the MMI-treated and the high-dose PTU-treated animals at PNWs 3 and 11. The serum 
      levels of thyroid-related hormones were depressed in the MMI and high-dose PTU 
      groups. FACS analysis revealed that the ATDs caused proportional changes in the 
      lymphoid cell subpopulations. The proportion of B cells among the total 
      lymphocytes was significantly decreased at PNW3, whereas that of T cells, 
      especially of inactive T cells, was dramatically increased. Moreover, the 
      proportion of CD4(+)CD25(+) regulatory T cells was significantly increased in the 
      spleen and peripheral blood at PNW3. Most of the above-described changes had 
      recovered to normal levels at PNW11. These results suggest that ATDs might have 
      temporal immunomodulatory effects on the developing immune system.
FAU - Nakamura, Ryosuke
AU  - Nakamura R
AD  - National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 
      158-8501, Japan.
FAU - Teshima, Reiko
AU  - Teshima R
FAU - Hachisuka, Akiko
AU  - Hachisuka A
FAU - Sato, Yuji
AU  - Sato Y
FAU - Takagi, Kayoko
AU  - Takagi K
FAU - Nakamura, Rika
AU  - Nakamura R
FAU - Woo, Gye-Hyeong
AU  - Woo GH
FAU - Shibutani, Makoto
AU  - Shibutani M
FAU - Sawada, Jun-Ichi
AU  - Sawada J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070904
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Surface)
RN  - 0 (CD71 antigen)
RN  - 0 (Lectins, C-Type)
RN  - 0 (NK Cell Lectin-Like Receptor Subfamily B)
RN  - 0 (Receptors, Transferrin)
RN  - 554Z48XN5E (Methimazole)
RN  - 721M9407IY (Propylthiouracil)
SB  - IM
MH  - Animals
MH  - Antigens, CD/analysis
MH  - Antigens, Surface/analysis
MH  - Female
MH  - Fetus/*drug effects/immunology
MH  - Flow Cytometry
MH  - Hypothyroidism/chemically induced/*immunology
MH  - Immune System/*drug effects
MH  - Lectins, C-Type/analysis
MH  - Lymphocyte Subsets/drug effects
MH  - Methimazole/*toxicity
MH  - NK Cell Lectin-Like Receptor Subfamily B
MH  - Organ Size/drug effects
MH  - Pregnancy
MH  - Propylthiouracil/*toxicity
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Transferrin/analysis
MH  - Spleen/drug effects/pathology
MH  - Thymus Gland/drug effects/pathology
EDAT- 2007/11/13 09:00
MHDA- 2008/01/25 09:00
CRDT- 2007/11/13 09:00
PHST- 2007/07/04 00:00 [received]
PHST- 2007/08/01 00:00 [revised]
PHST- 2007/08/14 00:00 [accepted]
PHST- 2007/11/13 09:00 [pubmed]
PHST- 2008/01/25 09:00 [medline]
PHST- 2007/11/13 09:00 [entrez]
AID - S1567-5769(07)00259-7 [pii]
AID - 10.1016/j.intimp.2007.08.012 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2007 Dec 15;7(13):1630-8. doi: 10.1016/j.intimp.2007.08.012. 
      Epub 2007 Sep 4.